At the molecular level, RBM3 acts indirectly by inhibiting Wnt/β-catenin pathway activation, which is required for bone metastasis of prostate cancer cells, thus enhancing cellular migration and invasion. The gene discussed is RBM3; the disease is prostate cancer.